Given that the production of IFNs is a ubiquitous host response following viral infection, the blockade of the AhR pathway to reduce mucin expression by epithelial cells may also be suitable to treat various viral infection-caused lung disorders such as SARS, MERS and Ebola. The gene discussed is AHR; the disease is viral infectious disease.